The emerging role of immunotoxins in leukemia and lymphoma

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Winkler, U ^a   Barth, S ^a   Schnell, R ^a   Diehl, V ^a   Engert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

cancer therapy; immunotoxins; minimal residual disease; monoclonal antibodies; review

Indexed keywords

ABRIN; BACTERIAL TOXIN; DIPHTHERIA TOXIN; GELONIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PLANT TOXIN; POKEWEED ANTIVIRUS PROTEIN; PSEUDOMONAS EXOTOXIN; RICIN; RICIN A; SAPORIN;

CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; IMMUNOGENICITY; LEUKEMIA; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; TOXIN ANALYSIS;

EID: 0031002375     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S139     Document Type: Conference Paper

References (46)

1. Moolten FL, Copperband SR. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science 1970; 169: 68-70.
2. Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin, and modeccin into the cytosol of HeLa cells. Exp Cell Res 1980; 126: 321-6.
3. Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988; 65: 329-35.
4. 1 tumor: Effect of immunotoxin valency and deglycosylation of the ricin A-chain. Cancer Res 1988; 48: 2626-31.
5. Thorpe PE, Wallace PM, Knowles PP et al. New coupling agents for the synthesis of immunotoxins containing a hindered disulphide bond with improved stability in vivo. Cancer Res 1987; 47: 5924-31.
6. Knowles PP, Thorpe PE. Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B. Ann Biochem 1987; 160: 440-3.
7. Roy DC, Griffin JD, Belvinet M et al. Anti-My9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 1991; 77: 2404-12.
8. Engert A, Burrows F, Jung W et al. Evaluation of ricin A-chain-containing immunotoxins directed against the CD30 antigen on potential reagents for the treatment of Hodgkin's disease. Cancer Res 1990; 50: 84-8.
9. Engert A, Martin G. Pfreundschuh M et al. Anti-tumor effects of ricin A-chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. Cancer Res 1990; 50: 2929-35.
10. Engert A, Martin G, Amlot P et al. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumor effects against human Hodgkin cells in vitro and solid Hodgkin tumors in mice. Int J Cancer 1991; 49: 450-6.
11. Winkler U, Gottstein C, Schön G et al. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 1994; 83: 466-75.
12. Schnell R, Linnartz C, Katouzi AA et al. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer 1995; 63: 238-44.
13. Jansen B, Vallera DA, Jaszcz DA et al. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin-A-chain immunotoxin DA7. Cancer Res 1992; 52: 1314-21.
14. Ghetie MA, Richardson J, Tucker K et al. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res 1991; 51: 5876-80.
15. Ghetie MA, Tucker K, Richardson J et al. The anti-tumor activity of an anti-CD22-immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 2315-20.
16. Thorpe PE, Wallace PM, Knowles PP et al. Improved anti-tumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 1988; 48: 6396-403.
17. Engert A, Gottstein C, Bohlen H et al. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int J Cancer 1995; 63: 304-9.
18. Vitetta ES, Stone M, Amlot P et al. A phase I immunotoxin trial in patients with B cell lymphoma. Cancer Res 1991; 15: 4052-8.
19. Amlot PL, Stone MJ, Cunningham D et al. A phase I study of an anti-CD22 deglycosylated ricin A chain immunotoxin in the treatment of B cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624-33
20. Sausville EA, Headlee D, Stetler-Stevenson M et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 1995; 85: 3457-65.
21. Stone MJ, Sausville EA, Fay JW et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin IgG-HD37-dgA in patients with B cell lymphoma. Blood 1996; 88; 1188-97.
22. Schnell R, Hatwig MT, Radszuhn A et al. A clinical phase I trial of an anti-CD25 deglycosylated ricin A-chain immunotoxin in patients with refractory Hodgkin's disease. Blood 1995; Nov (Suppl): 208.
23. Soler-Rodriguez AM, Ghetie MA, Oppenheimer-Marks N et al. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: Implications for vascular leak syndrome. Exp Cell Res 1993; 206: 227-34.
24. Grossbard ML, Freedman AS, Ritz J et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin - a phase I trial of daily bolus infusion. Blood 1992; 79: 576-85.
25. Grossbard ML, Lambert JM, Goldmacher VS et al. Anti-b4-blocked ricin - a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726-37.
26. Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83.
27. Grossbard ML, Gribben JG, Freedman AS et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263-71.
28. Esseltine D, Grossbard ML, McLaughlin P et al Anti-B4-blocked ricin (anti-B4-bR) immunotoxin (IT) in the treatment of B-cell lymphoma and leukemia. Abstracts of the Fourth International Symposium on Immunotoxins, Myrtle Beach, SC, 1995; 157.
29. 486Il-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547-54.
30. 486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73: 1276-85.
31. 389IL-2 in patients with NHL, HD, and CTCL. Abstracts of the Fourth International Symposium on Immunotoxins, Myrtle Beach, SC, 1995; 159.
32. Pai LH, FitzGerald DJ, Tepper M et al. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 1990; 50: 7750-3.
33. Byers VS, Austin EB, Clegg JA et al. Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies. J Clin Immunol 1993; 13: 406-12.
34. Jin FS, Youle RJ, Johnson VG et al. Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies. J Immunol 1991; 146: 1806-11.
35. Linsley PS, Wallace PM, Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792-5.
36. Riechmann L, Clark M, Waldmann H et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7.
37. Barbas III CF, Amberg W, Simonesits A et al. Selection of human anti-hapten antibodies from semisynthetic libraries. Gene 1993; 137: 57-62.
38. Uckun FM, Kersey JH, Vallera DA et al. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723-33.
39. Blazar BR, Filipovich AH, Kersey JH et al. T-cell depletion of donor marrow graft: Effects on graft-versus-host-disease and engraftment. In Gale RP, Champlin R (eds): Progress in Bone Marrow Transplantation. New York: Alan R. Liss 1987; 381-97.
40. Sands H. Radioimmunoconjugates: An overview of problems and promises. Antibody Immunoconj Radiopharmaceut 1988; 1: 213-26.
41. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993; 90: 8996-9000.
42. Falini B, Pasqualucci L, Flenghi L et al. Anti-CD30 immunotoxins: Experimental and clinical studies. Abstracts of the Fourth International Symposium on Immunotoxins. Myrtle Beach, SC, 1995; 160.
43. O'Day S, Fidias P, Arinielle PD et al. Phase II trial of bolus infusion anti-B4-blocked ricin (anti-B4-bR) in patients with B-cell non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1996; 15: 1386.
44. Epstein C, Lynch T, Shefner J et al. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer 1994; 8: 57-9.
45. 486IL-2) as a 6 hour intravenous infusion in patients with haematologic malignancies. Leuk Lymph 1994; 14: 257-62.
46. Pai LH, Wittes RE, Setser A et al. Phase I study of the immunotoxin LMB-1, an anti-cancer murine MAb B3, coupled to a recombinant form of the Pseudomonas exotoxin PE38. Proc Am Soc Clin Oncol 1996; 15: 1528.